Bifogade filer
Spago Nanomedical - Tumorad progress
Prenumeration
Du har en aktiv prenumeration.
Prenumerera på pressmeddelanden från Redeye via email.
Du prenumererar på följande språk.
Välj vilka språk du vill prenumerera på.
Modular Finance AB kommer att hantera vissa av dina personuppgifter om du väljer att prenumerera. Mer information om vår personuppgiftshantering finns här.
2024-08-23 10:34:00
Tumorad-01 is progressing towards the DMC meeting and the study is about to expand the number of patients as well as the number of cancer types represented. The cost base is contained and the recent funding has increased the cash position to SEK 47.7m. Our updated base case is SEK 1.0 (1.0), Bull case SEK 2.6 (2.6) and a Bear Case of SEK 0.2 (0.2).
Read more and download the Research Update.
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/